N,N-Dipropyldopamine is a dopamine receptor agonist.1,2,3 It decreases dihydrophenylalanine (DOPA) levels in the limbic forebrain and striatum of reserpinized rats (ED50s = 25 and 20 μmol/kg, respectively), as well as reduces homovanillic acid levels in rat striatum when administered at a dose of 80 μmol/kg.1 N,N-Dipropyldopamine (0.5-16 mg/kg) reduces spontaneous locomotor activity in mice, an effect that can be reversed by the antipsychotic spiroperidol.2,3
|1. Wikstr•m, H., Lindberg, P., Martinson, P., et al. Pivaloyl esters of N,N-dialkylated dopamine congeners. Central dopamine-receptor stimulating activity. J. Med. Chem. 21(9), 864-867 (1978).|2. Feenstra, M.G., Rollema, H., Horn, A.S., et al. Effect of dihydroxy-2-aminotetralin derivatives on dopamine metabolism in the rat striatum. Naunyn Schmiedebergs Arch. Pharmacol. 310(3), 219-225 (1980).|3. Costall, B., Lim, S.K., and Naylor, R.J. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice. Eur. J. Pharmacol. 73(2-3), 175-188 (1981).